SPRC vs. IMNN, FLGC, ERNA, ASBP, TXMD, ME, NEUP, ALVR, ABP, and NXTC
Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Imunon (IMNN), Flora Growth (FLGC), Ernexa Therapeutics (ERNA), Aspire Biopharma (ASBP), TherapeuticsMD (TXMD), 23andMe (ME), Neuphoria Therapeutics (NEUP), AlloVir (ALVR), Abpro (ABP), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.
SciSparc vs. Its Competitors
SciSparc (NASDAQ:SPRC) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.
In the previous week, Imunon had 3 more articles in the media than SciSparc. MarketBeat recorded 4 mentions for Imunon and 1 mentions for SciSparc. SciSparc's average media sentiment score of 0.00 beat Imunon's score of -0.02 indicating that SciSparc is being referred to more favorably in the media.
SciSparc has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Imunon has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
25.1% of SciSparc shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 6.0% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Imunon has a consensus price target of $15.50, indicating a potential upside of 1,859.54%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than SciSparc.
SciSparc has higher revenue and earnings than Imunon.
SciSparc's return on equity of 0.00% beat Imunon's return on equity.
Summary
Imunon beats SciSparc on 8 of the 14 factors compared between the two stocks.
Get SciSparc News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SciSparc Competitors List
Related Companies and Tools
This page (NASDAQ:SPRC) was last updated on 7/6/2025 by MarketBeat.com Staff
Free SPRC Stock Alerts